A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
Stavzor (DSC), Depakene (DSC)
Synonyms :
valproic acid
Class :
Anticonvulsants; Other
Dosage forms & Strengths
Capsule
250 mgÂ
Syrup
250mg/5ml
Complex partial seizures:
10-15 mg/kg orally daily; may increase to 5-10 mg/kg once in a week
Do not exceed 60 mg/kg a day
Conversion to Monotherapy:
Reduce the dosage of a concomitant medication by about 25% every 14 days; this dosage reduction may occur when valproate therapy is started or one to two weeks after the start of valproate therapy
simple and complex absence seizures:
Initial dose: 15 mg/kg orally divided 2-4 times a day; may increase to 5-10 mg/kg
Do not exceed 60 mg/kg a day
Dosage forms & Strengths
Capsule
250 mgÂ
Syrup
250mg/5ml
Complex partial seizures:
10-15 mg/kg orally daily; may increase to 5-10 mg/kg once in a week
Do not exceed 60 mg/kg a day
Conversion to Monotherapy:
Reduce the dosage of a concomitant medication by about 25% every 14 days; this dosage reduction may occur when valproate therapy is started or one to two weeks after the start of valproate therapy
simple and complex absence seizures:
Initial dose: 15 mg/kg orally divided 2-4 times a day; may increase to 5-10 mg/kg
Do not exceed 60 mg/kg a day
Refer adult dosing
they may diminish the serum concentration when combined with valproic acid
When valproic acid is used together with ouabain, this leads to reduction in valproic acid excretion
valproic acid: they may decrease the therapeutic effect of corticosteroids A1
valproic acid: they may decrease the therapeutic effect of corticosteroids A1
valproic acid: they may decrease the therapeutic effect of corticosteroids A1
valproic acid: they may decrease the therapeutic effect of corticosteroids A1
valproic acid: they may decrease the therapeutic effect of corticosteroids A1
valproic acid: they may decrease the therapeutic effect of corticosteroids J3
valproic acid: they may decrease the therapeutic effect of corticosteroids J3
valproic acid: they may decrease the therapeutic effect of corticosteroids J3
valproic acid: they may decrease the therapeutic effect of corticosteroids J3
when coupled with fentiazac, valproic acid's protein binding can be reduced
may alter the level by affecting CYP450 enzyme metabolism
reduction in the protein-binding efficacy of valproic acid can be seen when taken with bumadizone
the protein binding efficiency of valproic acid may be reduced when taken with mofebutazone
may have a decrease in excretion when combined with valproic acid
the severity of central nervous system depression can be raised when valproic acid is taken with zotepine
Frequency defined
10%
Nausea Â
Headache Â
Bleeding time increasedÂ
Thrombocytopenia Â
Tremor Â
AlopeciaÂ
Asthenia Â
Infection Â
Somnolence Â
Amblyopia Â
Diarrhea Â
Diplopia Â
Dizziness Â
DyspepsiaÂ
Nystagmus Â
Tinnitus Â
VomitingÂ
1-10%:Â
Ataxia Â
Increased appetite Â
Rash Â
Abdominal pain Â
Tremor Â
Back pain Â
Mood changes Â
Anxiety Â
Confusion Â
Abnormal gait Â
Paresthesia Â
HallucinationsÂ
Catatonia Â
Dysarthria Â
Tardive dyskinesiaÂ
Vertigo Â
Irregular menses Â
Weight gain Â
Frequency undefined:Â
Hepatic toxicityÂ
HyperammonaemiaÂ
AnorexiaÂ
Weight lossÂ
FracturesÂ
OsteoporosisÂ
OsteopeniaÂ
Valproic acid is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
Valproic acid is contraindicated during pregnancyÂ
Breastfeeding warnings:Â Â
The drug is excreted in the breastmilk; hence monitor the infant during breastfeeding Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name:Â valproic acidÂ
Pronounced: val-pro-ic ace-idÂ
Why do we use valproic acid?Â
valproic acid is a medication that is used for various medical purposes. Here are some common reasons for its use: